scholarly article | Q13442814 |
P356 | DOI | 10.1080/17482960600888156 |
P698 | PubMed publication ID | 17364435 |
P50 | author | Paul H. Gordon | Q37837296 |
Hiroshi Mitsumoto | Q90084178 | ||
P2093 | author name string | Petra Kaufmann | |
Bruce Levin | |||
Richard Buchsbaum | |||
John L P Thompson | |||
Alexandra I Barsdorf | |||
Vanessa Battista | |||
Rachel Arbing | |||
Gilbero Levy | |||
Jacquelina Montes | |||
QALS study group | |||
P2860 | cites work | Intraclass correlations: uses in assessing rater reliability | Q28296226 |
ALS issues in clinical trials. Missing data | Q30974065 | ||
ALSFRS-R. | Q34362989 | ||
A clinical trial of creatine in ALS. | Q40469445 | ||
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis | Q43569621 | ||
A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 | ||
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis | Q44562245 | ||
A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. | Q46433161 | ||
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group | Q46827288 | ||
The ALSFRSr predicts survival time in an ALS clinic population | Q47867763 | ||
Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials | Q48570656 | ||
Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. | Q52980048 | ||
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 | ||
P433 | issue | 1 | |
P921 | main subject | multicenter clinical trial | Q6934595 |
P304 | page(s) | 42-46 | |
P577 | publication date | 2007-02-01 | |
P1433 | published in | Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders | Q15759048 |
P1476 | title | Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial | |
P478 | volume | 8 |
Q57165581 | A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene |
Q51636543 | A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. |
Q36177001 | A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement |
Q37227808 | A plug-and-play brain-computer interface to operate commercial assistive technology |
Q48266568 | A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. |
Q37317971 | Accurate ALSFRS-R scores can be generated from retrospective review of clinic notes |
Q88409196 | Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial |
Q40797810 | Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis |
Q35042461 | Amyotrophic lateral sclerosis patients' self-reported satisfaction with assistive technology |
Q33885448 | Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model |
Q42668576 | Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study |
Q57290390 | Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort |
Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS |
Q35501852 | Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis |
Q37513013 | Clinical outcome measures in spinal muscular atrophy |
Q92289432 | Dominant Heterogeneity of Upper and Lower Motor Neuron Degeneration to Motor Manifestation of Involved Region in Amyotrophic Lateral Sclerosis |
Q44317416 | Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses |
Q46710455 | Elective termination of respiratory therapy in amyotrophic lateral sclerosis |
Q37867784 | Emerging targets and treatments in amyotrophic lateral sclerosis |
Q48211357 | Eye tracking communication devices in amyotrophic lateral sclerosis: impact on disability and quality of life |
Q51066498 | Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. |
Q90317315 | First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound |
Q44215931 | Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study |
Q52731289 | Global motor unit number index sum score for assessing the loss of lower motor neurons in amyotrophic lateral sclerosis. |
Q43739867 | Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality |
Q41553914 | Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy |
Q35367839 | Identification of personal factors in motor neurone disease: a pilot study |
Q89962935 | Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer |
Q30488429 | Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database |
Q58096837 | Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis |
Q51643746 | Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease |
Q48052700 | Multidisciplinary ALS clinics in the USA: A comparison of those who attend and those who do not. |
Q43603184 | Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients |
Q39215223 | Non-self-sufficiency as a primary outcome measure in ALS trials |
Q92378843 | Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS |
Q35847073 | Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial |
Q41837997 | Outcome measures in amyotrophic lateral sclerosis clinical trials |
Q34429131 | Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study |
Q30494108 | Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. |
Q34026859 | Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]. |
Q30359919 | Speech Movement Measures as Markers of Bulbar Disease in Amyotrophic Lateral Sclerosis. |
Q55982486 | Spinal muscular atrophy |
Q60634009 | The Clinical and Radiological Spectrum of Hippocampal Pathology in Amyotrophic Lateral Sclerosis |
Q50204979 | The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS. |
Q56773744 | The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis |
Q36441993 | The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials |
Q42619674 | Use of the international classification of functioning, disability and health to describe patient-reported disability: a comparison of motor neurone disease, Guillain-Barré syndrome and multiple sclerosis in an Australian cohort |
Q45284849 | Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure |
Q35776967 | What would brain-computer interface users want? Opinions and priorities of potential users with amyotrophic lateral sclerosis |
Search more.